Literature DB >> 25891774

Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.

Kimberly M Lovell1, Kevin J Frankowski2, Edward L Stahl1, Stephen R Slauson2, Euna Yoo2, Thomas E Prisinzano2, Jeffrey Aubé2, Laura M Bohn1.   

Abstract

Kappa opioid receptor (KOR) modulation is a promising target for drug discovery efforts due to KOR involvement in pain, depression, and addiction behaviors. We recently reported a new class of triazole KOR agonists that displays significant bias toward G protein signaling over βarrestin2 recruitment; interestingly, these compounds also induce less activation of ERK1/2 map kinases than the balanced agonist, U69,593. We have identified structure-activity relationships around the triazole scaffold that allows for decreasing the bias for G protein signaling over ERK1/2 activation while maintaining the bias for G protein signaling over βarrestin2 recruitment. The development of novel compounds, with different downstream signaling outcomes, independent of G protein/βarrestin2 bias, provides a more diverse pharmacological toolset for use in defining complex KOR signaling and elucidating the significance of KOR-mediated signaling.

Entities:  

Keywords:  Functional selectivity; G protein coupling; GPCR; MAP kinase; arrestin; biased agonism

Mesh:

Substances:

Year:  2015        PMID: 25891774      PMCID: PMC4830356          DOI: 10.1021/acschemneuro.5b00092

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  39 in total

1.  A novel method for analyzing extremely biased agonism at G protein-coupled receptors.

Authors:  Edward L Stahl; Lei Zhou; Frederick J Ehlert; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-02-13       Impact factor: 4.436

2.  A simple method for quantifying functional selectivity and agonist bias.

Authors:  Terry Kenakin; Christian Watson; Vanessa Muniz-Medina; Arthur Christopoulos; Steven Novick
Journal:  ACS Chem Neurosci       Date:  2011-12-20       Impact factor: 4.418

3.  Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

4.  Identification of novel functionally selective κ-opioid receptor scaffolds.

Authors:  Kate L White; Alex P Scopton; Marie-Laure Rives; Ruslan V Bikbulatov; Prabhakar R Polepally; Peter J Brown; Terrance Kenakin; Jonathan A Javitch; Jordan K Zjawiony; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

5.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

6.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

7.  Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Authors:  Ashlee Van't Veer; Anita J Bechtholt; Sara Onvani; David Potter; Yujun Wang; Lee-Yuan Liu-Chen; Günther Schütz; Elena H Chartoff; Uwe Rudolph; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

8.  Buprenorphine treatment of refractory depression.

Authors:  J A Bodkin; G L Zornberg; S E Lukas; J O Cole
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

9.  Kappa opioid agonists suppress chloroquine-induced scratching in mice.

Authors:  Saadet Inan; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2004-10-19       Impact factor: 4.432

10.  Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Authors:  Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

View more
  25 in total

Review 1.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

2.  Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.

Authors:  Tarsis F Brust; Jenny Morgenweck; Susy A Kim; Jamie H Rose; Jason L Locke; Cullen L Schmid; Lei Zhou; Edward L Stahl; Michael D Cameron; Sarah M Scarry; Jeffrey Aubé; Sara R Jones; Thomas J Martin; Laura M Bohn
Journal:  Sci Signal       Date:  2016-11-29       Impact factor: 8.192

Review 3.  Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Authors:  Srikrishnan Mallipeddi; David R Janero; Nikolai Zvonok; Alexandros Makriyannis
Journal:  Biochem Pharmacol       Date:  2016-11-24       Impact factor: 5.858

4.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

Review 5.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

6.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

7.  Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor.

Authors:  Laura M Bohn; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2017-07-05       Impact factor: 4.345

Review 8.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

9.  G protein signaling-biased agonism at the κ-opioid receptor is maintained in striatal neurons.

Authors:  Jo-Hao Ho; Edward L Stahl; Cullen L Schmid; Sarah M Scarry; Jeffrey Aubé; Laura M Bohn
Journal:  Sci Signal       Date:  2018-08-07       Impact factor: 8.192

Review 10.  Biased agonism: An emerging paradigm in GPCR drug discovery.

Authors:  Zoran Rankovic; Tarsis F Brust; Laura M Bohn
Journal:  Bioorg Med Chem Lett       Date:  2015-12-09       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.